C12N9/503

GENETICALLY ENCODED INFRARED FLUORESCENT PROTEASE REPORTERS
20170188835 · 2017-07-06 ·

The invention described herein features infrared fluorescent protease reporters (iProteases) and methods of use thereof. The iProteases can be used in in vivo and in vitro assays to detect protease activity and disease states associated with protease activity. In a still further embodiment, the present invention provides a kit comprising any of the above described polynucleotides. In a further aspect, the present invention provides a method of in vivo optical imaging. In a still further embodiment, the in vivo imaging is performed in a living animal. In a further aspect, the present invention provides a method of detecting protease activity, the method comprising expressing a polypeptide according to any of those described above in a cell.

PAENIBACILLUS LARVAE TREATMENT WITH PHAGE LYSIN FOR AMERICAN FOULBROOD DISEASE
20170183642 · 2017-06-29 ·

Materials and methods for treating and preventing American Foulbrood disease in honeybees, such as materials and methods for using phage lysin enzymes to lyse Paenibacillus larvae, are provided herein.

BIOFILM PREVENTION, DISRUPTION AND TREATMENT WITH BACTERIOPHAGE LYSIN

The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphylococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation.

Isolated recombinant cDNA

The routine use of antibiotics to battle Streptococcal pathogens has produced a new class of superbugmulti-drug resistant streptococci resulting in a need for new antimicrobials. The LambdaSa2 prophage endolysin gene harbors an amidase-5 (endopeptidase), an amidase-4 (glycosidase) domain and two Cpl-7 cell wall-binding domains. This endolysin can digest the cell walls of Streptococcus agalactiae, Streptococcus pneumoniae and Staphylococcus aureus. Turbidity reduction and plate lysis assays indicate that this peptidoglycan hydrolase also shows strong lytic activity toward Streptococcus pyogenes, Streptococcus dysgalactiae, Streptococcus uberis, Streptococcus equi, GES, and GGS. Deletion analysis on the His-tagged version of this gene further indicates that the N-terminal endopeptidase domain is minimally active in the absence of a Cpl-7 domain when lysing cells from without; however, with both Cpl-7 domains, it achieves a higher specific activity than the full length protein (on some strains) and shows weak activity against two Coagulase Negative Staphylococci, Staphylococcus hyicus and Staphylococcus xyloses.

SYNTHETIC GENES AND GENETIC CONSTRUCTS
20170002379 · 2017-01-05 ·

The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.

A SYNTHETIC SYSTEM FOR TUNABLE THRESHOLDING OF PROTEIN SIGNALS

Disclosed herein include methods, compositions, and kits suitable for use in thresholding of protein signals. There are provided, in some embodiments, synthetic protein circuits that respond to inputs only above or below a certain threshold concentration. In some embodiments, the threshold value itself is tunable. Methods of treating a disease or disorder characterized by aberrant signaling are provided in some embodiments.